A Phase 2 interventional study of placebo-Q2W and HMI-115-120mg-Q4W in Androgenetic Alopecia, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-04.
Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Alopecia with a site in China — 12 open to participants now, 14 under way, 4 of them phase 3. Alopecia · China.
Among the 33 studies in Alopecia with a site in China, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 in phase 2, and was the 7th registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →12 of the 33 studies in Alopecia with a site in China are open now. Recruiting first, the newest first:
Zhang Han · Sites in China
Ages 18–55 · Men only
The First Affiliated Hospital of Xinxiang Medical College · Sites in China
Ages 20–65 · Men only · Healthy volunteers
Shenzhen People's Hospital · Sites in China
Ages 18–60
Shenzhen People's Hospital · Sites in China
Ages 18–35 · Men only
Vita Green Pharmaceutical (H.K.) Ltd. · Sites in China
Ages 18–60 · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 65 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 7
First in 2018; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 128 across the 32 interventional studies, 12 across the 1 observational. Of the 17 that completed or were terminated, 2 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 33 have an industry lead sponsor. The 10 most frequent:
Hope Medicine (Nanjing) Co., Ltd is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Hope Medicine (Nanjing) Co., Ltd has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06622824Phase 3Suzhou Kintor Pharmaceutical Inc,To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia | 2027-10-20 |
| NCT07603544The First Affiliated Hospital of Xinxiang Medical CollegeMulti-Omics Insights Into Androgenetic Alopecia | 2026-12 |
| NCT07370519Shenzhen People's HospitalTopical Application of Lactobacillus Reuteri for Androgenetic Alopecia | 2027-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Alopecia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has any of the following conditions within 6 weeks prior to Screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
placebo, 0mg/vials
Drug: placebo-Q2W
HMI-115, 60mg/vials
Drug: HMI-115-120mg-Q4W
HMI-115, 60mg/vials
Drug: HMI-115-240mg-Q4W
HMI-115, 60mg/vials
Drug: HMI-115, 240mg-Q2W
placebo, 0mg,SC,Q2W,12 cycles
HMI-115, 120mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)
HMI-115, 240mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)
HMI-115, 240mg,SC,Q2W,12 cycles
The Rate of Target Arean Hair Count (TAHC)
The mean change in TAHC of non-vellus from baseline
Time frame: 24 Weeks
Hair Growth State Assessed by Hair Growth Questionnaire Assessment (HGQA)
To assess the hair growth by 7-question questionnaire and summary the number and percentage of subjects in each category for each HGQA question.
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Target Area Hair Count (TAHC) change from baseline
The mean change in TAHC of non-vellus from Baseline
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Rate of Target Area Hair Width (TAHW)
The mean change in TAHW of non-vellus from baseline
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Investigator Global Assessment (IGA)
Summary of subject number and percentage in each IGA category
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Subject Self-Assessment (SSA)
Summary of subject number and percentage in each SSA category
Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks
Norwood-Hamilton Grade change from baseline
Summary of subject number and percentage in each grade of Norwood-Hamilton Scale
Time frame: 12 weeks, 24 weeks, and 36 weeks
Frequencies and percentages of Adverse event (AE)
Frequency and percentages of subjects with treatment-emergent AE (TEAE) will be calculated and TEAE will be summarized by systematic organ classification (SOC), preferred term (PT), relationship to study treatment, maximum severity, whether resulting in death, whether resulting in study treatment discontinuation, belong to serious AE (SAE) or not, belong to events of special interest (AESI) or not.
Time frame: 36Weeks
Blood Pressure change from baseline
Descriptive statistics summarizing changes in blood pressure (systolic and diastolic) will be compared between baseline levels and each predetermined time point.
Time frame: 36 Weeks
Pulse change from baseline
Descriptive statistics summarizing changes in pulse will be compared between baseline levels and each predetermined time point.
Time frame: 36 Weeks
Body temperature change from baseline
Descriptive statistics summarizing changes in body temperature will be compared between baseline levels and each predetermined time point.
Time frame: 36 Weeks
Respiratory rate
Descriptive statistics summarizing changes in respiratory rate will be compared between baseline levels and each predetermined time point.
Time frame: 36 Weeks
Complete or brief physical examination, at a minimum of General appearance, HEENT (head, eyes, ears, nose, throat), Neck, Lung/pulmonary, Chest, Neurological or not, Extremities,ect.to assess the physical health state.
Physical examination findings by body system will be summarized, presented with frequency counts and percentages. A complete or brief physical examination will be performed at Visit 1, Visit 2, End of Treatment Visit and Follow-up Visit. Height (cm) and weight (kg) will be measured and body mass index will be calculated and recorded at specified period.
Time frame: 36 Weeks
Concomitant Medication
Concomitant medication usage will be summarized by the number and proportion of subjects and classified by the World Health Organization Drug Dictionary (WHO DD) based on Anatomical Therapeutic Chemical Classification System (ATC) code level 3.
Time frame: 36 Weeks
Change in twelve-lead electrocardiogram parameters
Change in electrocardiogram parameters including heart rate (HR), QRS, RR, PR, and QT interval (QTcF and QTcB) relative to baseline will be summarized descriptively by visits and groups. The within-group changes from baseline to each visit will be summarized and will be compared with a paired t-test for continuous measurements. Subject number and percentage with other clinically significant electrocardiogram findings in each visit will be summarized by groups. A general assessment of the 12-lead electrocardiogram will be presented as normal, abnormal clinical significance, or abnormal no clinical significance.
Time frame: 36 Weeks
Clinical laboratory tests of hematology
Descriptive statistics summarizing changes in results of clinical laboratory tests of hematology from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.
Time frame: 36 Weeks
Clinical laboratory tests of coagulation
Descriptive statistics summarizing changes in results of clinical laboratory tests of coagulation from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.
Time frame: 36 Weeks
Clinical laboratory tests of clinical chemistry
Descriptive statistics summarizing changes in results of clinical laboratory tests of clinical chemistry from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.
Time frame: 36 Weeks
Clinical laboratory tests of urinalysis
Descriptive statistics summarizing changes in results of clinical laboratory tests of urinalysis from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.
Time frame: 36 Weeks
Clinical laboratory tests of hormones
Descriptive statistics summarizing changes in results of clinical laboratory tests of hormones from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.
Time frame: 36 Weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Aug 2024, 11 months.
Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is close to that.
Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HMI-115
Hope Medicine (Nanjing) Co., Ltd